Dr. Ahn on the Significance of the KEYNOTE-177 Trial in mCRC

Partner | Cancer Centers | <b>Mayo Clinic Cancer Center</b>

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC).

The new standard of care for patients with MSI-H mCRC is based on findings from the KEYNOTE-177 trial, which were presented during the 2020 ASCO Virtual Scientific Program, says Ahn.

The study showed a doubling in progression-free survival with pembrolizumab (Keytruda) versus standard chemotherapy in patients with newly diagnosed MSI-H mCRC, Ahn explains.

Prior to these data, a patient with MSI-H mCRC ​that harbors an NTRK fusion would have ​received chemotherapy in the frontline setting, followed by either a checkpoint inhibitor or an ​NTRK-directed TKI​, says Ahn.

However, pembrolizumab monotherapy has now become the new frontline standard of care for ​this subgroup ofpatients, Ahn concludes.